Abstract
•Transcatheter aortic valve replacement for native aortic valve regurgitation is feasible but with modest technical success (79.8%).•Balloon-expandable valve use is linked to lower 30-day major adverse cardiac events versus self-expanding valve in high-risk patients.•Long-term outcomes driven by patient risk, not valve type.•Dedicated native aortic regurgitation systems still needed to improve procedural safety.